CN112089732A - A radix Achyranthis joint fluid product and its application in treating knee arthritis and shoulder arthritis - Google Patents
A radix Achyranthis joint fluid product and its application in treating knee arthritis and shoulder arthritis Download PDFInfo
- Publication number
- CN112089732A CN112089732A CN202011159734.6A CN202011159734A CN112089732A CN 112089732 A CN112089732 A CN 112089732A CN 202011159734 A CN202011159734 A CN 202011159734A CN 112089732 A CN112089732 A CN 112089732A
- Authority
- CN
- China
- Prior art keywords
- joint
- achyranthes bidentata
- achyranthes
- arthritis
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 20
- 206010003246 arthritis Diseases 0.000 title claims abstract description 16
- 240000000031 Achyranthes bidentata Species 0.000 claims abstract description 25
- 210000001179 synovial fluid Anatomy 0.000 claims abstract description 15
- 210000003127 knee Anatomy 0.000 claims abstract description 9
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 210000000629 knee joint Anatomy 0.000 claims abstract description 6
- 230000000415 inactivating effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 15
- 230000002779 inactivation Effects 0.000 claims description 10
- 238000009928 pasteurization Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims 5
- 241000427159 Achyranthes Species 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003435 antirheumatic agent Substances 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 abstract description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 11
- 229940010747 sodium hyaluronate Drugs 0.000 description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 11
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
The invention discloses a achyranthes bidentata joint fluid product and application thereof in treating knee and shoulder arthritis, wherein the achyranthes bidentata joint fluid product is prepared by the following steps: s1, selecting adult healthy buffalos; s2, collecting the joint synovial fluid of the freshly killed achyranthes bidentata in an aseptic environment; s3, inactivating bacteria and viruses in the buffalo knee joint synovial fluid; and S4, cold chain cold storage. The invention is used for treating knee and shoulder arthritis of human body, has high lubricity and high goodness of fit, can nourish the surrounding tissues in the joint cavity of human body, and has good antirheumatic and anti-bony spur effects.
Description
Technical Field
The invention relates to the technical field of biological products, in particular to a achyranthes bidentata joint fluid product and application thereof in treating knee and shoulder arthritis.
Background
At present, sodium hyaluronate injection is used as a main medicine for treating arthritis and scapulohumeral periarthritis of a human body, and the sodium hyaluronate injection is injected into a diseased joint cavity to play a role in improving joints. However, the clinical effect of the sodium hyaluronate injection is not ideal, and the main reasons are as follows: firstly, the lubricity of sodium hyaluronate is poor; secondly, the sodium hyaluronate injection has low inosculation with the joint fluid of human articular cavity; thirdly, the sodium hyaluronate injection has no nutrition effect on tissues around the articular surface of the articular cavity; fourthly, the sodium hyaluronate does not contain anti-rheumatic factors and anti-bony spur polypeptides.
Disclosure of Invention
In order to make up for the defects in the prior art, the invention provides a achyranthes bidentata joint fluid product which has better effect than sodium hyaluronate when used for treating knee and shoulder arthritis of a human body.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a product of achyranthes bidentata joint fluid is prepared by the following steps:
s1, selecting adult healthy buffalos;
s2, collecting the joint synovial fluid of the freshly killed achyranthes bidentata in an aseptic environment;
s3, inactivating bacteria and viruses in the buffalo knee joint synovial fluid;
and S4, cold chain cold storage.
Further, in step S2, the method comprises placing the achyranthes bidentata joint on a sterile table, inserting a sterile disposable syringe into the cavity of the achyranthes bidentata joint, extracting synovial fluid from the achyranthes bidentata joint, and transferring the synovial fluid to a sterile container.
Further, in step S3, the inactivation of the bacteria and viruses is performed by any one of short-wave UVC ultraviolet method, pasteurization method, dry heat inactivation method, and organic solvent inactivation method.
Further, in step S3, the inactivation of the bacteria and viruses is performed by a pasteurization method, i.e., the achyranthes bidentata joint synovial fluid is heated to 62-65 ℃ and kept for 30 min.
Further, in step S4, the temperature of cold storage is 2-8 ℃.
The application of the achyranthes bidentata joint fluid product in treating knee and shoulder arthritis.
Compared with the prior art, the invention has the following beneficial technical effects:
the achyranthes bidentata joint fluid product has natural antirheumatic factors and antirheumatic polypeptide, has better lubricity on human joints than sodium hyaluronate, has high coincidence degree with the physiological components of the human joint fluid, can nourish the tissues around the joint cavity of the human body, and has good antirheumatic and antirheumatic effects on the knee and shoulder arthritis of the human body clinically.
Detailed Description
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
Example 1
A product of achyranthes bidentata joint fluid is prepared by the following steps:
1. adult healthy buffalos are selected, and freshly slaughtered buffalos are collected, and placed in a refrigerator.
2. Transferring the knee joint of the Buffalo into a sterile workbench, puncturing the joint cavity of the Buffalo with a sterile disposable syringe, extracting the synovial fluid of the Buffalo joint, and transferring the Bombalo joint synovial fluid into a sterile container.
3. The method for inactivating the bacterial virus of the achyranthes bidentata joint synovial fluid can be any one of a short wave UVC ultraviolet method, a pasteurization method, a dry heat inactivation method and an organic solvent inactivation method. The preferred embodiment is a pasteurization method, namely heating the buffalo knee joint synovial fluid to 62-65 ℃ and keeping the temperature for 30 min.
4. And cold chain cold storage at 2-8 ℃ for later use.
The product can be used for treating knee and shoulder arthritis by direct injection, 2ml once, once a week, and 5 weeks as a treatment course.
In order to prove the effect of the achyranthes bidentata joint fluid product in treating knee and shoulder arthritis of a human body, clinically 20 degenerative knee arthritis patients aged about 65 years who are not effective in treatment by sodium hyaluronate in one course of treatment are selected, and after the achyranthes bidentata joint fluid product is used for treatment in one course of treatment, 16 effective cases (with 12 remarkable effects) and 4 ineffective cases are selected; in addition, 20 cases of patients with non-bony arthritis who are 45-55 years old and are ineffectively treated by sodium hyaluronate after one course of treatment are selected, the patients show that knee joints are soft and uncomfortable, and are afraid of wind and cold, and after the patients are treated by the achyranthes bidentata joint fluid product for one course of treatment, 17 cases of the patients (with 14 cases of remarkable effects) are available, and 3 cases of the patients are ineffectively treated; after treatment, the two batches of patients are followed up regularly, and no adverse reaction or rejection reaction is found.
Although the present invention has been described in detail with reference to the embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.
Claims (6)
1. The achyranthes bidentata joint fluid product is characterized by being prepared by the following steps:
s1, selecting adult healthy buffalos;
s2, collecting the joint synovial fluid of the freshly killed achyranthes bidentata in an aseptic environment;
s3, inactivating bacteria and viruses in the buffalo knee joint synovial fluid;
and S4, cold chain cold storage.
2. The aqueous achyranthes root joint fluid preparation of claim 1, wherein: in step S2, the specific operation method is that the achyranthes bidentata joint is taken and placed on a sterile workbench, a sterile disposable syringe is used to pierce into the cavity of the achyranthes bidentata joint, and the synovial fluid of the achyranthes bidentata joint is extracted and transferred to a sterile container.
3. The aqueous achyranthes root joint fluid preparation of claim 2, wherein: in step S3, the inactivation of the bacteria and viruses is performed by any one of short-wave UVC ultraviolet method, pasteurization, dry heat inactivation, and organic solvent inactivation.
4. The aqueous achyranthes root joint fluid preparation of claim 3, wherein: in the step S3, the inactivation of the bacteria and viruses adopts a pasteurization method, namely, the achyranthes bidentata joint synovial fluid is heated to 62-65 ℃ and kept for 30 min.
5. The aqueous achyranthes root joint fluid preparation of claim 4, wherein: in step S4, the temperature of cold storage is 2-8 ℃.
6. Use of a liquid preparation of achyranthes bidentata as claimed in any one of claims 1 to 5 for the treatment of arthritis of the knee and shoulder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011159734.6A CN112089732A (en) | 2020-10-27 | 2020-10-27 | A radix Achyranthis joint fluid product and its application in treating knee arthritis and shoulder arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011159734.6A CN112089732A (en) | 2020-10-27 | 2020-10-27 | A radix Achyranthis joint fluid product and its application in treating knee arthritis and shoulder arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112089732A true CN112089732A (en) | 2020-12-18 |
Family
ID=73785834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011159734.6A Pending CN112089732A (en) | 2020-10-27 | 2020-10-27 | A radix Achyranthis joint fluid product and its application in treating knee arthritis and shoulder arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112089732A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060083787A1 (en) * | 2002-12-03 | 2006-04-20 | Meader Charles P | Method of treating mammalian joint maladies by biological fluid transplantation |
| JP2012031123A (en) * | 2010-08-02 | 2012-02-16 | Kracie Home Products Ltd | Hyaluronic acid production promoter |
| CN108452052A (en) * | 2018-03-29 | 2018-08-28 | 青岛市城阳区第二人民医院 | A kind of Cape jasmine breast Nitrate Yellow Powder for treating knee joint osseous arthritis |
-
2020
- 2020-10-27 CN CN202011159734.6A patent/CN112089732A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060083787A1 (en) * | 2002-12-03 | 2006-04-20 | Meader Charles P | Method of treating mammalian joint maladies by biological fluid transplantation |
| JP2012031123A (en) * | 2010-08-02 | 2012-02-16 | Kracie Home Products Ltd | Hyaluronic acid production promoter |
| CN108452052A (en) * | 2018-03-29 | 2018-08-28 | 青岛市城阳区第二人民医院 | A kind of Cape jasmine breast Nitrate Yellow Powder for treating knee joint osseous arthritis |
Non-Patent Citations (3)
| Title |
|---|
| MARK D. KOHN 等: ""Human synoviocyte lubricin and bovine synovial fluid lubricin equally improve gliding resistance in a canine model in vitro"", vol. 21 * |
| 张惟杰: "《复合多糖生化研究技术》", vol. 1, 上海科学技术出版社, pages: 267 * |
| 徐锋 等: ""透明质酸钠对兔膝骨性关节炎关节液中TNF-α、IL-6和MMP-3的影响"", vol. 5, no. 13, pages 3904 - 3905 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101810855B (en) | II-type collagen joint cartilage fluid and preparation method thereof | |
| Gubin et al. | Ilizarov method for bone lengthening and defect management: review of contemporary literature | |
| Henning et al. | Platelet-rich plasma in the foot and ankle | |
| RU2609201C1 (en) | Method for obtaining osteoplastic material | |
| US20210008239A1 (en) | Medical Ozone Sterile Isotonic Saline Solution And Preparation Method And Application Thereof | |
| CN104940905A (en) | Medicine composition for promoting wound healing after operation and preparation method thereof | |
| RU2017103186A (en) | STERILIZED THERMOGEL COMPOSITION | |
| Mutchnick et al. | Nonendoscopic, minimally invasive calvarial vault remodeling without postoperative helmeting for sagittal synostosis | |
| Chiang et al. | Is hyperbaric oxygen therapy indispensable for saving mutilated hand injuries? | |
| CN109106610A (en) | A kind of sterilization process of no antiseptic activity collagen mask | |
| CN102284057A (en) | Method for preparing placenta polypeptide injection | |
| Helber et al. | External fixation in forearm shaft fractures | |
| CN112089732A (en) | A radix Achyranthis joint fluid product and its application in treating knee arthritis and shoulder arthritis | |
| CN102441023B (en) | Injection composition for treating orthopedic diseases | |
| KR20150131864A (en) | Pharmaceutical composition comprising mixture of DNA fragments separated from fish's semen or testis for the prevention or treatment of rotator cuff tear | |
| CN102920994B (en) | Pharmaceutical composition containing animal bone polypeptide | |
| CN111840525A (en) | Composition for treating thromboangiitis and preparation method thereof | |
| CN109316629B (en) | Injection type bone repair material and preparation method and application thereof | |
| CN105031622A (en) | Pharmaceutical composition capable of promoting wound healing, and preparation method thereof | |
| US6527760B1 (en) | Out-patient joint lavage kit and protocol | |
| JPH07206888A (en) | Placenta extract and its preparation | |
| CN106215230A (en) | A kind of preparation method of glass protecting wound surface gel | |
| CN107213089A (en) | One kind is dispelled striae of pregnancy reparation, anti-wrinkle skin care item and preparation method thereof | |
| CN100355847C (en) | Biocollagen and its production process | |
| Stallworth et al. | Superior oblique palsy after facial feminization surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201218 |